Request for Information (RFI): Inviting Comments and Suggestions on Updating the NIH Mission Statement, 60470-60471 [2023-18989]
Download as PDF
<![CDATA[
60470
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
Dated: August 28, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2023–18939 Filed 8–31–23; 8:45 am]
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development; Notice of Closed
Meetings
BILLING CODE 4140–01–P
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Initial Review
Group; Function, Integration, and
Rehabilitation Sciences Study Section.
Date: October 3, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Eunice
Kennedy Shriver National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Room 2125D, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Moushumi Paul, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Eunice Kennedy Shriver National
Institute of Child Health and Human
Development, National Institutes of Health,
6710B Rockledge Drive, Room 2125D,
Bethesda, MD 20892, (301) 496–3596,
moushumi.paul@nih.gov.
Name of Committee: Eunice Kennedy
Shriver National Institute of Child Health
and Human Development Initial Review
Group; Reproduction, Andrology, and
Gynecology Study Section.
Date: October 26, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose Avenue,
North Bethesda, MD 20852.
Contact Person: Jagpreet Singh Nanda,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, National Institutes of
Health, 6710B Rockledge Drive, Room 2121C,
Bethesda, MD 20892, (301) 451–4454,
jagpreet.nanda@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.865, Research for Mothers
and Children, National Institutes of Health,
HHS)
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Request for Information (RFI): Inviting
Comments and Suggestions on
Updating the NIH Mission Statement
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Request for information.
This Notice is a Request for
Information (RFI) inviting feedback on a
proposed update to the National
Institutes of Health (NIH) mission
statement. As the largest public funder
of biomedical and behavioral research
in the world, NIH works to turn
scientific discoveries into better health
for all. This RFI will inform NIH’s
efforts to update its mission statement to
ensure that it reflects the NIH mission
as accurately as possible. Review of this
entire RFI notice is encouraged to
ensure your response is comprehensive
and to have a full understanding of how
it will be used.
DATES: Comments must be received by
11:59:59 p.m. (ET) on November 24,
2023 to ensure consideration. After the
public comment period has closed, the
comments received will be considered
in a timely manner by NIH.
ADDRESSES: All comments must be
submitted electronically on the
submission website at https://
rfi.grants.nih.gov/?s=64caaa8bb
1112e46ad0a1d52. Responses to this
RFI are voluntary and may be submitted
anonymously. Please do not include any
personally identifiable information or
any information that you do not wish to
make public. Proprietary, classified,
confidential, or sensitive information
should not be included in your
response. The Government will use the
information submitted in response to
this RFI at its discretion. The
Government reserves the right to use
any submitted information on public
websites, in reports, in summaries of the
state of the science, in any possible
resultant solicitation(s), grant(s), or
cooperative agreement(s), or in the
development of future funding
opportunity announcements. This RFI is
for informational and planning purposes
only and is not a solicitation for
applications or an obligation on the part
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
of the Government to provide support
for any ideas identified in response to
it. Please note that the Government will
not pay for the preparation of any
information submitted or for use of that
information.
We look forward to your input and
hope that you will share this RFI
opportunity with your colleagues.
FOR FURTHER INFORMATION CONTACT:
Questions about this RFI should be
directed to Lauren Brodd, Ph.D., Office
of the Director, National Institutes of
Health, RFIMissionStatement@nih.gov,
301–827–5152.
SUPPLEMENTARY INFORMATION: NIH is the
nation’s medical research agency —
making important discoveries that
improve health and save lives. NIH’s
current mission statement at https://
www.nih.gov/about-nih/what-we-do/
mission-goals is ‘‘to seek fundamental
knowledge about the nature and
behavior of living systems and the
application of that knowledge to
enhance health, lengthen life, and
reduce illness and disability.’’
In 2021, NIH established the Advisory
Committee to the Director (ACD)
Working Group on Diversity, Subgroup
on Individuals with Disabilities (https://
www.acd.od.nih.gov/working-groups/
disabilitiessubgroup.html) to dedicate
time and resources to identify strategies
to support individuals with disabilities.
The Subgroup issued a report (https://
acd.od.nih.gov/documents/
presentations/12092022_WGD_
Disabilities_Subgroup_Report.pdf) in
December 2022 that contains several
recommendations, including updating
the NIH mission statement. The ACD
adopted the Working Group’s
recommendations and provided them to
the NIH Director. The report stated:
‘‘One immediate action for the NIH to
support disability inclusion is to remove
the language of ‘reducing disability’
from the NIH mission statement. The
current mission statement could be
interpreted as perpetuating ableist
beliefs that disabled people are flawed
and need to be ‘fixed’.’’
To address this suggestion, NIH
Leadership committed to evaluate the
mission statement, particularly
reviewing the inclusion of the phrase
‘‘reduce [. . .] disability’’, and to update
it to better reflect the current and future
vision for the agency. Following
discussions among NIH Leadership and
with NIH subject matter experts, a
proposed revised mission statement was
developed.
Information Requested
This RFI invites input from interest
groups throughout the scientific
E:\FR\FM\01SEN1.SGM
01SEN1
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
research, advocacy, and clinical practice
communities, those employed by NIH or
at institutions receiving NIH support,
and the public, on a proposed revised
mission statement. The bolded language
reflects differences between the current
and proposed mission statements.
• Current mission statement: ‘‘To
seek fundamental knowledge about the
nature and behavior of living systems
and the application of that knowledge to
enhance health, lengthen life, and
reduce illness and disability.’’
• Proposed revised mission
statement: ‘‘To seek fundamental
knowledge about the nature and
behavior of living systems and to apply
that knowledge to optimize health and
prevent or reduce illness for all people.’’
Input sought about the proposed
revised mission statement includes, but
is not limited to, the following:
• Feedback on whether the proposed
new mission statement reflects the goals
and objectives as outlined in the NIHWide Strategic Plan for Fiscal Years
2021–2025 (https://www.nih.gov/sites/
default/files/about-nih/strategic-planfy2021-2025-508.pdf).
• Suggestions for specific language
that could be added to the proposed
mission statement and why.
• Feedback on any specific language
that could be removed from the
proposed mission statement and why.
NIH encourages organizations (e.g.,
patient advocacy groups, professional
societies) to submit a single response
reflective of the views of the
organization or its membership.
Dated: August 29, 2023.
Tara A. Schwetz,
Acting Principal Deputy Director, National
Institutes of Health.
[FR Doc. 2023–18989 Filed 8–31–23; 8:45 am]
Dated: August 28, 2023.
Ann Ferrero,
Public Health Analyst.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–18911 Filed 8–31–23; 8:45 am]
BILLING CODE 4162–20–P
Substance Abuse and Mental Health
Services Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Fiscal Year (FY) 2023 Notice of
Supplemental Funding Opportunity
Substance Abuse and Mental Health
Services Administration
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
lotter on DSK11XQN23PROD with NOTICES1
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) is supporting supplemental
funding in the scope of the parent award
SUMMARY:
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
to the 36 Rural Emergency Medical
Services Training Grant (REMS)
recipients funded under Notice of
Funding Opportunity (NOFO) TI–23–
011. These recipients have a project end
date of September 29, 2024. The
supplemental funding is to provide the
opioid antagonist medication, naloxone,
that can be used to treat respiratory
depression in suspected opioid
overdose patients, and for the
procurement of emergency equipment
used to rapidly reverse the effects of
opioid overdoses. Recipients may
receive up to $49,000 for the purchase
of naloxone and up to $49,000 for
purchasing equipment, for a total of
$98,000 per recipient.
FOR FURTHER INFORMATION CONTACT:
Humberto Carvalho, Email:
Humberto.Carvalho@samhsa.hhs.gov,
Phone: (240) 276–2974.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: Rural
Emergency Medical Services Training
TI–23–011.
Assistance Listing Number: 93.243.
Authority: The REMS Training grants
are authorized under Section 330J of the
Public Health Service Act, as amended
(42 U.S.C. 254c15).
Justification: This is not a formal
request for application. Assistance will
only be provided to the 36 REMS
recipients funded in FY 2023 funded
under Rural Emergency Medical
Services Training Grant Funding
Opportunity TI–23–011, based on the
receipt of a satisfactory application and
associated budget. The purpose of the
supplement is to further expand and
enhance REMS grant activities;
therefore, only current recipients are
eligible.
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
60471
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
SUMMARY:
E:\FR\FM\01SEN1.SGM
01SEN1
]]>Agencies
[Federal Register Volume 88, Number 169 (Friday, September 1, 2023)]
[Notices]
[Pages 60470-60471]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18989]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Request for Information (RFI): Inviting Comments and Suggestions
on Updating the NIH Mission Statement
AGENCY: National Institutes of Health, HHS.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: This Notice is a Request for Information (RFI) inviting
feedback on a proposed update to the National Institutes of Health
(NIH) mission statement. As the largest public funder of biomedical and
behavioral research in the world, NIH works to turn scientific
discoveries into better health for all. This RFI will inform NIH's
efforts to update its mission statement to ensure that it reflects the
NIH mission as accurately as possible. Review of this entire RFI notice
is encouraged to ensure your response is comprehensive and to have a
full understanding of how it will be used.
DATES: Comments must be received by 11:59:59 p.m. (ET) on November 24,
2023 to ensure consideration. After the public comment period has
closed, the comments received will be considered in a timely manner by
NIH.
ADDRESSES: All comments must be submitted electronically on the
submission website at https://rfi.grants.nih.gov/?s=64caaa8bb1112e46ad0a1d52. Responses to this RFI are voluntary and
may be submitted anonymously. Please do not include any personally
identifiable information or any information that you do not wish to
make public. Proprietary, classified, confidential, or sensitive
information should not be included in your response. The Government
will use the information submitted in response to this RFI at its
discretion. The Government reserves the right to use any submitted
information on public websites, in reports, in summaries of the state
of the science, in any possible resultant solicitation(s), grant(s), or
cooperative agreement(s), or in the development of future funding
opportunity announcements. This RFI is for informational and planning
purposes only and is not a solicitation for applications or an
obligation on the part of the Government to provide support for any
ideas identified in response to it. Please note that the Government
will not pay for the preparation of any information submitted or for
use of that information.
We look forward to your input and hope that you will share this RFI
opportunity with your colleagues.
FOR FURTHER INFORMATION CONTACT: Questions about this RFI should be
directed to Lauren Brodd, Ph.D., Office of the Director, National
Institutes of Health, [email protected], 301-827-5152.
SUPPLEMENTARY INFORMATION: NIH is the nation's medical research agency
-- making important discoveries that improve health and save lives.
NIH's current mission statement at https://www.nih.gov/about-nih/what-we-do/mission-goals is ``to seek fundamental knowledge about the nature
and behavior of living systems and the application of that knowledge to
enhance health, lengthen life, and reduce illness and disability.''
In 2021, NIH established the Advisory Committee to the Director
(ACD) Working Group on Diversity, Subgroup on Individuals with
Disabilities (https://www.acd.od.nih.gov/working-groups/disabilitiessubgroup.html) to dedicate time and resources to identify
strategies to support individuals with disabilities. The Subgroup
issued a report (https://acd.od.nih.gov/documents/presentations/12092022_WGD_Disabilities_Subgroup_Report.pdf) in December 2022 that
contains several recommendations, including updating the NIH mission
statement. The ACD adopted the Working Group's recommendations and
provided them to the NIH Director. The report stated: ``One immediate
action for the NIH to support disability inclusion is to remove the
language of `reducing disability' from the NIH mission statement. The
current mission statement could be interpreted as perpetuating ableist
beliefs that disabled people are flawed and need to be `fixed'.''
To address this suggestion, NIH Leadership committed to evaluate
the mission statement, particularly reviewing the inclusion of the
phrase ``reduce [. . .] disability'', and to update it to better
reflect the current and future vision for the agency. Following
discussions among NIH Leadership and with NIH subject matter experts, a
proposed revised mission statement was developed.
Information Requested
This RFI invites input from interest groups throughout the
scientific
[[Page 60471]]
research, advocacy, and clinical practice communities, those employed
by NIH or at institutions receiving NIH support, and the public, on a
proposed revised mission statement. The bolded language reflects
differences between the current and proposed mission statements.
Current mission statement: ``To seek fundamental knowledge
about the nature and behavior of living systems and the application of
that knowledge to enhance health, lengthen life, and reduce illness and
disability.''
Proposed revised mission statement: ``To seek fundamental
knowledge about the nature and behavior of living systems and to apply
that knowledge to optimize health and prevent or reduce illness for all
people.''
Input sought about the proposed revised mission statement includes,
but is not limited to, the following:
Feedback on whether the proposed new mission statement
reflects the goals and objectives as outlined in the NIH-Wide Strategic
Plan for Fiscal Years 2021-2025 (https://www.nih.gov/sites/default/files/about-nih/strategic-plan-fy2021-2025-508.pdf).
Suggestions for specific language that could be added to
the proposed mission statement and why.
Feedback on any specific language that could be removed
from the proposed mission statement and why.
NIH encourages organizations (e.g., patient advocacy groups,
professional societies) to submit a single response reflective of the
views of the organization or its membership.
Dated: August 29, 2023.
Tara A. Schwetz,
Acting Principal Deputy Director, National Institutes of Health.
[FR Doc. 2023-18989 Filed 8-31-23; 8:45 am]
BILLING CODE 4140-01-P
